MedTrace Logo

Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis

NCT02180828 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2017-05-02

Study results available
· View outcomes & findings →

Summary

The study is focused to prove that the efficacy and safety of Clotrimazole vaginal tablet vs Fluconazole for the treatment of severe vulvovaginal candidiasis

Conditions

  • Candidiasis, Vulvovaginal

Interventions

DRUG

Clotrimazole vaginal tablet

2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)

DRUG

Fluconazole

2 doses of 150 mg oral Fluconazole (at day1 and day4)

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Peking University Shenzhen Hospital

    lead OTHER

Principal Investigators

  • Shangrong Fan, M.D. · Peking University Shenzhen Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
48 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02180828 on ClinicalTrials.gov